This company listing is no longer active
BLR Stock Overview
BLIRT S.A. engages in the manufacture and sale of recombinant enzymes for the life science industry.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 1/6 |
Rewards
Risk Analysis
+ 1 more risk
BLIRT S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł14.90 |
52 Week High | zł15.90 |
52 Week Low | zł6.20 |
Beta | -1.65 |
1 Month Change | 0% |
3 Month Change | 65.56% |
1 Year Change | 5.08% |
3 Year Change | 2,157.58% |
5 Year Change | 1,121.31% |
Change since IPO | 127.48% |
Recent News & Updates
Recent updates
Market Cool On BLIRT S.A.'s (WSE:BLR) Earnings Pushing Shares 26% Lower
Oct 02BLIRT S.A. (WSE:BLR) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 02BLIRT's (WSE:BLR) Earnings Are Of Questionable Quality
May 19Will Weakness in BLIRT S.A.'s (WSE:BLR) Stock Prove Temporary Given Strong Fundamentals?
Jan 14With EPS Growth And More, BLIRT (WSE:BLR) Is Interesting
Dec 09Shareholder Returns
BLR | PL Biotechs | PL Market | |
---|---|---|---|
7D | 0% | 0.07% | 2.3% |
1Y | 5.1% | -17.6% | 35.3% |
Return vs Industry: BLR exceeded the Polish Biotechs industry which returned -30.9% over the past year.
Return vs Market: BLR exceeded the Polish Market which returned -23.4% over the past year.
Price Volatility
BLR volatility | |
---|---|
BLR Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 5.0% |
10% most volatile stocks in PL Market | 9.5% |
10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: BLR's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine BLR's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | 75 | Thierry Bernard | https://www.blirt.eu |
BLIRT S.A. engages in the manufacture and sale of recombinant enzymes for the life science industry. It offers proteins and enzymes, such as proteinases, RNase inhibitors, polymerases, nucleases, ligases, and other proteins; and molecular biology reagents, including DNA and RNA extraction, PCR and real-time PCR, reverse transcriptions, and RNA related products. BLIRT S.A. was founded in 1994 and is headquartered in Gdansk, Poland.
BLIRT S.A. Fundamentals Summary
BLR fundamental statistics | |
---|---|
Market cap | zł261.14m |
Earnings (TTM) | zł7.57m |
Revenue (TTM) | zł39.77m |
34.5x
P/E Ratio6.6x
P/S RatioIs BLR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BLR income statement (TTM) | |
---|---|
Revenue | zł39.77m |
Cost of Revenue | zł5.68m |
Gross Profit | zł34.09m |
Other Expenses | zł26.52m |
Earnings | zł7.57m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 11, 2022
Earnings per share (EPS) | 0.43 |
Gross Margin | 85.72% |
Net Profit Margin | 19.02% |
Debt/Equity Ratio | 0.001% |
How did BLR perform over the long term?
See historical performance and comparison